



## **FOR IMMEDIATE RELEASE**

### **NeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes at ISEV2019 Annual Meeting**

**ATLANTA and DETROIT, April 22, 2019** – NeurExo Sciences, LLC (NXS), a subsidiary of NeuroTrauma Sciences, LLC, and biotechnology company focused on the development of exosome therapies, and Henry Ford Health System (HFHS), a non-profit organization, today announced that HFHS will be presenting new data on exosomes in an oral presentation and poster presentation at the International Society for Extracellular Vesicles (ISEV) 2019 Annual Meeting being held April 24-28, 2019 in Kyoto, Japan.

Lead presenter of the oral presentation will be Zhenggang Zhang, MD, PhD, Senior Scientist, Henry Ford Health System. The presenting researchers are all from the laboratories of Michael Chopp, Ph.D., Vice Chairman, Department of Neurology; Scientific Director, Neurosciences Institute; Zoltan J. Kovacs Chair of Neuroscience Research at Henry Ford Health System in Detroit; and Distinguished Professor of Physics at Oakland University in Rochester, Michigan.

#### **Presentation Details**

**Oral Presentation: OF11.01: *Exosomes from cerebral endothelial cells suppress chemotherapy-induced peripheral neuropathy and sensitize anti-tumor effects of platinum drugs***

**Day:** 4/26/2019  
**Session Title:** Symposium Session 11: EV Therapeutics I  
**Session Time:** 8:30 AM - 10:00 AM JST  
**Presentation Time:** 8:30 AM-8:45 AM JST  
**Room:** Level B1, Hall B

**Poster Presentation: PT10.09: *Comprehensive proteomics and microRNA analyses of adult neural stem cell derived exosomes after stroke***

**Day:** 4/25/2019  
**Poster Session:** Thursday Poster Session  
**Session Title:** PT10: EVs and Stem Cells  
**Session Time:** 3:00-3:30 PM and 4:30:00 PM JST  
**Room:** Level 3, Hall A

In addition, John-Claude Sautel, Vice President of Corporate Development, NeuroTrauma Sciences, and Benjamin Buller, PhD, Assistant Scientist, Henry Ford Health System and Scientific Advisor of NeurExo Sciences, will be presenting an overview of NeurExo and its exosome technology:

#### **Product Theatre**

**Presentation:** *Targeting brain injuries with exosomes: a path to clinical translation in stroke and TBI*  
**Day:** 4/25/2019  
**Presentation Time:** 4:00-4:15 PM JST  
**Room:** Exhibit Hall

## **About Exosomes**

Exosomes are small extracellular vesicles that transport DNA, RNAs, lipids and proteins between cells, allowing organs, tissues and cells to communicate with one another and elicit specific biological responses based on their cargo. MicroRNAs transported by exosomes regulate gene translation and play primary roles in mediating a vast array of biological functions, including immunomodulation and the potential to enable multiple pathways of neurovascular restoration.

## **About the Chopp Lab in the Department of Neurology and the Neurosciences Institute at Henry Ford Hospital**

Dr. Chopp is dedicated to translational research in neuroscience, and he and his group are recognized as foremost authorities on exosomes and microRNA for treatment of neurological injury and disease. The focus of the laboratory is the pathophysiology of stroke and traumatic brain injury; mechanisms of neuroprotection, and cell-based, biologic (e.g. exosomes), molecular and pharmacological neurorestorative therapies for stroke, traumatic brain injury, and neurodegenerative disease. Dr. Chopp has approximately 750 peer reviewed publications and has received numerous prestigious research awards. His laboratory, comprising 70 researchers and staff, is one of the leading research centers in the world in translational neuroscience and restorative neurology and was the first lab to use mesenchymal stem cells (MSCs) as well as exosomes derived from MSCs and other sources, to treat stroke, TBI, and neurodegenerative diseases. His lab has been awarded more than \$80 million in total funding and has 19 active NIH grants.

## **About NeurExoSciences**

NeurExo Sciences, LLC, a privately-held biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, was formed in 2018 to advance Henry Ford's pioneering technology involving exosomes as extracellular vesicles enriched with microRNA for the purpose of treating stroke, traumatic brain injury (TBI) including concussion, and neuropathies. NXS has worldwide commercial rights to product candidates resulting from the exosome and miRNA IP and sponsored research generated by the lab.

###

For further information, please contact:

### **NeurExo/NeuroTrauma Sciences**

John-Claude Saltiel  
General Manager  
917-796-7749  
jc.saltiel@neurotraumasciences.com

### **SMP Communications**

Susan Pietropaolo  
201-923-2049  
susan@smpcommunications.com

### **Henry Ford Health System**

Jeffrey Adkins  
Public Relations Specialist  
(586) 307-2027  
jadkins6@hfhs.org